Justin Seltzer1, Thomas C Scotton2, Keiko Kang3, Gabriel Zada3,4,5, John D Carmichael6,4. 1. Department of Neurosurgery, Keck School of Medicine of USC, 1200 North State St., Los Angeles, CA, 90033, USA. jseltzer@usc.edu. 2. Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. 3. Department of Neurosurgery, Keck School of Medicine of USC, 1200 North State St., Los Angeles, CA, 90033, USA. 4. USC Pituitary Center, Keck School of Medicine of USC, Los Angeles, CA, USA. 5. Zilka Neurogenetics Institute, Keck School of Medicine of USC, Los Angeles, CA, USA. 6. Division of Endocrinology, Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA.
Abstract
INTRODUCTION: Prolactinomas are the most common functional pituitary adenomas. Current classification systems rely on phenotypic elements and have few molecular markers for complementary classification. Treatment protocols for prolactinomas are also devoid of molecular targets, leaving those refractory to standard treatments without many options. METHODS: A systematic literature review was performed utilizing the PRISMA guidelines. We aimed to summarize prior research exploring gene and protein expression in prolactinomas in order to highlight molecular variations associated with tumor development, growth, and prolactin secretion. A PubMed search of select MeSH terms was performed to identify all studies reporting gene and protein expression findings in prolactinomas from 1990 to 2014. RESULTS: 1392 abstracts were screened and 51 manuscripts were included in the analysis, yielding 54 upregulated and 95 downregulated genes measured by various direct and indirect analytical methods. Of the many genes identified, three upregulated (HMGA2, HST, SNAP25), and three downregulated (UGT2B7, Let7, miR-493) genes were selected for further analysis based on our subjective identification of strong potential targets. CONCLUSIONS: Many significant genes have been identified and validated in prolactinomas and most have not been fully analyzed for therapeutic and diagnostic potential. These genes could become candidate molecular targets for biomarker development and precision drug targeting as well as catalyze deeper research efforts utilizing next generation profiling/sequencing techniques, particularly genome scale expression and epigenomic analyses.
INTRODUCTION:Prolactinomas are the most common functional pituitary adenomas. Current classification systems rely on phenotypic elements and have few molecular markers for complementary classification. Treatment protocols for prolactinomas are also devoid of molecular targets, leaving those refractory to standard treatments without many options. METHODS: A systematic literature review was performed utilizing the PRISMA guidelines. We aimed to summarize prior research exploring gene and protein expression in prolactinomas in order to highlight molecular variations associated with tumor development, growth, and prolactin secretion. A PubMed search of select MeSH terms was performed to identify all studies reporting gene and protein expression findings in prolactinomas from 1990 to 2014. RESULTS: 1392 abstracts were screened and 51 manuscripts were included in the analysis, yielding 54 upregulated and 95 downregulated genes measured by various direct and indirect analytical methods. Of the many genes identified, three upregulated (HMGA2, HST, SNAP25), and three downregulated (UGT2B7, Let7, miR-493) genes were selected for further analysis based on our subjective identification of strong potential targets. CONCLUSIONS: Many significant genes have been identified and validated in prolactinomas and most have not been fully analyzed for therapeutic and diagnostic potential. These genes could become candidate molecular targets for biomarker development and precision drug targeting as well as catalyze deeper research efforts utilizing next generation profiling/sequencing techniques, particularly genome scale expression and epigenomic analyses.
Entities:
Keywords:
Gene expression; Lactotroph; Pituitary adenoma; Prolactin; Prolactinoma; Protein expression
Authors: T Chile; M L Corrêa-Giannella; M A H Z Fortes; M D Bronstein; M B Cunha-Neto; D Giannella-Neto; R R Giorgi Journal: J Endocrinol Invest Date: 2011-01-26 Impact factor: 4.256
Authors: M Musat; M Korbonits; B Kola; N Borboli; M R Hanson; A M Nanzer; J Grigson; S Jordan; D G Morris; M Gueorguiev; M Coculescu; S Basu; A B Grossman Journal: Endocr Relat Cancer Date: 2005-06 Impact factor: 5.678
Authors: Fabio Rotondo; Kalman Kovacs; Bernd W Scheithauer; Eva Horvath; Cecil David Bell; Ricardo V Lloyd; Michael Cusimano Journal: Appl Immunohistochem Mol Morphol Date: 2008-10
Authors: M Theodoropoulou; I Cavallari; L Barzon; D M D'Agostino; T Ferro; T Arzberger; Y Grübler; L Schaaf; M Losa; F Fallo; V Ciminale; G K Stalla; U Pagotto Journal: Endocr Relat Cancer Date: 2004-06 Impact factor: 5.678
Authors: Stanley B DeVore; Coleman H Young; Guangyuan Li; Anitha Sundararajan; Thiruvarangan Ramaraj; Joann Mudge; Faye Schilkey; Aaron Muth; Paul R Thompson; Brian D Cherrington Journal: Mol Cell Biol Date: 2018-09-14 Impact factor: 4.272
Authors: María José García-Barrado; Enrique J Blanco; María Carmen Iglesias-Osma; Marta Carretero-Hernández; Leonardo Catalano-Iniesta; Virginia Sanchez-Robledo; Manuel Carretero; Julio Joaquín Herrero; Sixto Carrero; José Carretero Journal: Int J Mol Sci Date: 2017-11-01 Impact factor: 5.923